Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

RGT-61159

RGT-61159 Phase 3 (planned, not yet registered)

Rgenta Therapeutics · Phase 3 · Not yet recruiting · Enrollment 150

Registry id n/r

Catalyst Phase 3 start (company plan). Q1 2027. Company release 10.22.2026: start planned 1Q 2027.

ArmPopulationDoseEstimandComparatorEfficacy
RGT-61159 84 mg + best supportive carebiomarker-selected R/M ACC (about 150 total, 2:2:1)84 mgITTplacebon/r
RGT-61159 60 mg + best supportive carebiomarker-selected R/M ACC60 mgITTplacebon/r
Placebo + best supportive carebiomarker-selected R/M ACCplaceboITTn/rn/r

No efficacy figure is in this file for this study.